FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326416867> ?p ?o ?g. }

• W2326416867 abstract "Prostate cancer (PC) is the most common type of cancer in males and the second leading cause of male cancer deaths in the United States. Circulating tumor cells (CTCs) are commonly found in the blood of patients suffering from mestatic disease and the capture of these cells is important in the study of disease progression. Existing devices use the EpCAM antibody which can capture circulating epithelial cancer cells, but also leads to a large number of leukocyte contamination. We have developed a microfluidic chip functionalized with an antibody to the prostate-specific membrane antigen (PSMA), which captures prostate CTCs with high purity and efficiency. This chip is designed with a staggered obstacle array that maximizes the CTC-wall interactions while minimizing the interactions with the other cells in the blood. PSMA-positive or -negative PC cells were spiked into blood from healthy donors, and we calculated capture rates to be ∼80%. Next, blood samples from patients (n = 20) with castrate resistant prostate cancer (CRPC) were run through the device and CTCs were captured and enumerated. CTCs were found in 90% of samples tested with the number captured averaging 27 ± 4 cells per mL of blood with a capture purity of 62 ± 2%. We plan to use this device to elucidate the molecular basis of CRPC clinical response to taxane treatment, which is the only class of chemotherapy drugs shown to improve survival in this type of PC. Previous data from our laboratory has shown that taxane treatment of PC cells inhibits the ligand-induced androgen receptor (AR) nuclear accumulation and transcriptional activation of androgen response element (ARE) containing genes including the prostate-specific antigen (PSA). These results implicate microtubules (MTs) in AR trafficking and suggest that the clinical activity of taxanes in CRPC may be mediated in part by the drugs’ ability to stabilize MTs and inhibit AR transcriptional activity. We plan to capture CTCs using the PSMA-specific microfluidic device from CRPC patients receiving taxane treatment and analyze them for AR subcellular distribution and correlate clinical response to taxane treatment. Our microfluidic device is a novel, specific, and improved technology to capture prostate CTCs that will allow us to better define the molecular basis of taxane treatment in CRPC patients.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1145." @default.
• W2326416867 created "2016-06-24" @default.
• W2326416867 creator A5019109535 @default.
• W2326416867 creator A5026075148 @default.
• W2326416867 creator A5028308977 @default.
• W2326416867 creator A5028538472 @default.
• W2326416867 creator A5032346666 @default.
• W2326416867 creator A5070626557 @default.
• W2326416867 creator A5071996306 @default.
• W2326416867 date "2010-04-15" @default.
• W2326416867 modified "2023-09-26" @default.
• W2326416867 title "Abstract 1145: Analysis of circulating tumor cells from castrate resistant prostate cancer patients captured via a microfluidic device using the prostate specific membrane antigen antibody" @default.
• W2326416867 doi "https://doi.org/10.1158/1538-7445.am10-1145" @default.
• W2326416867 hasPublicationYear "2010" @default.
• W2326416867 type Work @default.
• W2326416867 sameAs 2326416867 @default.
• W2326416867 citedByCount "0" @default.
• W2326416867 crossrefType "proceedings-article" @default.
• W2326416867 hasAuthorship W2326416867A5019109535 @default.
• W2326416867 hasAuthorship W2326416867A5026075148 @default.
• W2326416867 hasAuthorship W2326416867A5028308977 @default.
• W2326416867 hasAuthorship W2326416867A5028538472 @default.
• W2326416867 hasAuthorship W2326416867A5032346666 @default.
• W2326416867 hasAuthorship W2326416867A5070626557 @default.
• W2326416867 hasAuthorship W2326416867A5071996306 @default.
• W2326416867 hasConcept C104317684 @default.
• W2326416867 hasConcept C121608353 @default.
• W2326416867 hasConcept C126322002 @default.
• W2326416867 hasConcept C143998085 @default.
• W2326416867 hasConcept C145059251 @default.
• W2326416867 hasConcept C147483822 @default.
• W2326416867 hasConcept C159654299 @default.
• W2326416867 hasConcept C185592680 @default.
• W2326416867 hasConcept C203014093 @default.
• W2326416867 hasConcept C20518536 @default.
• W2326416867 hasConcept C2776235491 @default.
• W2326416867 hasConcept C2777511904 @default.
• W2326416867 hasConcept C2779013556 @default.
• W2326416867 hasConcept C2780192828 @default.
• W2326416867 hasConcept C502942594 @default.
• W2326416867 hasConcept C530470458 @default.
• W2326416867 hasConcept C55493867 @default.
• W2326416867 hasConcept C61238886 @default.
• W2326416867 hasConcept C71924100 @default.
• W2326416867 hasConcept C96232424 @default.
• W2326416867 hasConceptScore W2326416867C104317684 @default.
• W2326416867 hasConceptScore W2326416867C121608353 @default.
• W2326416867 hasConceptScore W2326416867C126322002 @default.
• W2326416867 hasConceptScore W2326416867C143998085 @default.
• W2326416867 hasConceptScore W2326416867C145059251 @default.
• W2326416867 hasConceptScore W2326416867C147483822 @default.
• W2326416867 hasConceptScore W2326416867C159654299 @default.
• W2326416867 hasConceptScore W2326416867C185592680 @default.
• W2326416867 hasConceptScore W2326416867C203014093 @default.
• W2326416867 hasConceptScore W2326416867C20518536 @default.
• W2326416867 hasConceptScore W2326416867C2776235491 @default.
• W2326416867 hasConceptScore W2326416867C2777511904 @default.
• W2326416867 hasConceptScore W2326416867C2779013556 @default.
• W2326416867 hasConceptScore W2326416867C2780192828 @default.
• W2326416867 hasConceptScore W2326416867C502942594 @default.
• W2326416867 hasConceptScore W2326416867C530470458 @default.
• W2326416867 hasConceptScore W2326416867C55493867 @default.
• W2326416867 hasConceptScore W2326416867C61238886 @default.
• W2326416867 hasConceptScore W2326416867C71924100 @default.
• W2326416867 hasConceptScore W2326416867C96232424 @default.
• W2326416867 hasLocation W23264168671 @default.
• W2326416867 hasOpenAccess W2326416867 @default.
• W2326416867 hasPrimaryLocation W23264168671 @default.
• W2326416867 hasRelatedWork W2007917223 @default.
• W2326416867 hasRelatedWork W2022027327 @default.
• W2326416867 hasRelatedWork W2075518898 @default.
• W2326416867 hasRelatedWork W2394991672 @default.
• W2326416867 hasRelatedWork W2502559504 @default.
• W2326416867 hasRelatedWork W2771066073 @default.
• W2326416867 hasRelatedWork W2783882412 @default.
• W2326416867 hasRelatedWork W3014214351 @default.
• W2326416867 hasRelatedWork W3189738538 @default.
• W2326416867 hasRelatedWork W2617244872 @default.
• W2326416867 isParatext "false" @default.
• W2326416867 isRetracted "false" @default.
• W2326416867 magId "2326416867" @default.
• W2326416867 workType "article" @default.